Literature DB >> 7720174

Extensive and saturable accumulation of paclitaxel by the human platelet.

M D Wild1, U K Walle, T Walle.   

Abstract

Little is known about the cellular distribution of paclitaxel in humans. In the present study we examined the distribution of [3H]-paclitaxel in human blood. When 1 microM paclitaxel was incubated with fresh blood at 37 degrees C, the platelet/plasma concentration ratio was 240 +/- 17 (mean +/- SEM), whereas the red blood cell (RBC)/plasma concentration ratio was only 0.59 +/- 0.05. In kinetics experiments using platelet-rich plasma, we observed that the platelet accumulation of paclitaxel was highly temperature- and concentration-dependent. Scatchard analysis of the 37 degrees C uptake data demonstrated a dissociation constant (Kapp) of 0.80 +/- 0.10 microM and a maximal binding capacity of 672 +/- 102 pmol/10(9) platelets. It is proposed that the platelet accumulation of paclitaxel reflects binding to microtubules and may serve as a useful model for binding to less accessible cellular sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720174     DOI: 10.1007/BF00685730

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  6 alpha-Hydroxytaxol: isolation and identification of the major metabolite of taxol in human liver microsomes.

Authors:  G N Kumar; J E Oatis; K R Thornburg; F J Heldrich; E S Hazard; T Walle
Journal:  Drug Metab Dispos       Date:  1994 Jan-Feb       Impact factor: 3.922

2.  Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells.

Authors:  P W Gout; L L Wijcik; C T Beer
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

3.  The reversible binding of vinblastine to platelets: implications for therapy.

Authors:  J G Kelton; J W McDonald; R M Barr; I Walker; W Nicholson; P B Neame; C Hamid; T Y Wong; J Hirsh
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

4.  Mammalian platelet adrenoceptors.

Authors:  R Kerry; M C Scrutton; R B Wallis
Journal:  Br J Pharmacol       Date:  1984-01       Impact factor: 8.739

5.  Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein.

Authors:  G N Kumar; U K Walle; K N Bhalla; T Walle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1993-06

6.  Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

Authors:  P H Wiernik; E L Schwartz; A Einzig; J J Strauman; R B Lipton; J P Dutcher
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

7.  Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.

Authors:  D S Sonnichsen; C A Hurwitz; C B Pratt; J J Shuster; M V Relling
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

8.  Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation.

Authors:  G N Kumar; U K Walle; T Walle
Journal:  J Pharmacol Exp Ther       Date:  1994-03       Impact factor: 4.030

9.  Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol.

Authors:  J W Harris; A Katki; L W Anderson; G N Chmurny; J V Paukstelis; J M Collins
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

10.  Taxol binds to polymerized tubulin in vitro.

Authors:  J Parness; S B Horwitz
Journal:  J Cell Biol       Date:  1981-11       Impact factor: 10.539

View more
  4 in total

1.  A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

Authors:  N Siddiqui; A V Boddy; H D Thomas; N P Bailey; L Robson; M J Lind; A H Calvert
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

3.  Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer.

Authors:  Wenwu Xiao; Juntao Luo; Teesta Jain; John W Riggs; Harry P Tseng; Paul T Henderson; Simon R Cherry; Douglas Rowland; Kit S Lam
Journal:  Int J Nanomedicine       Date:  2012-03-27

4.  Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

Authors:  H L McLeod; L S Murray; J Wanders; A Setanoians; M A Graham; N Pavlidis; B Heinrich; W W ten Bokkel Huinink; D J Wagener; S Aamdal; J Verweij
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.